
    
      This is an open-label Phase 4 study designed to collect additional data to assess the safety
      and efficacy of VIGIV [CNJ-016, Vaccinia Immune Globulin Intravenous (Human), sterile
      solution] in the first 100 consented patients treated with VIGIV.
    
  